Video
Dr. Shore on phase 3 ARASENS trial: “This is undoubtedly game-changing”
Author(s):
“If you're going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.
In this video, Neal D. Shore, MD, FACS, discusses his impressions of the key study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium.Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
